Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

Open-Label, Fixed-Sequence Study To Estimate The Pharmacokinetic Interaction Between Multiple Dose Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01290211

Enrollment

Registered

2011-02-04

Start date

2011-04-30

Completion date

2011-06-30

Last updated

2011-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

maraviroc, fosamprenavir, drug interaction, pharmacokinetics, HIV, AIDS, CCR5, protease inhibitor

Brief summary

This is will be an open-label, fixed-sequence, multiple dose crossover study in 2 cohorts of 14 healthy male and/or female subjects, to estimate the effect of maraviroc on the pharmacokinetics of amprenavir and ritonavir and fosamprenavir/ritonavir on the pharmacokinetics of maraviroc.

Interventions

DRUGMaraviroc

maraviroc 300 mg BID x 5 days

DRUGFosamprenavir/ritonavir

fosamprenavir/ritonavir 700/100 mg BID x 10 days

DRUGMaraviroc + Fosamprenavir/ritonavir

maraviroc 300 mg BID + fosamprenavir/ritonavir 700/100 mg BID x 10 days

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive. * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2. * Total body weight \>50 kg (110 lbs).

Exclusion criteria

* History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening. * Positive result for HIV, Hepatitis B or Hepatitis C virus. * Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication. * Known hypersensitivity or history of allergy to sulfonamides.

Design outcomes

Primary

Measure	Time frame
Maraviroc plasma pharmacokinetic parameters: AUCτ, Cmax, and Cτ.	Period 1, Day 5
Amprenavir and ritonavir plasma pharmacokinetic parameters: AUCτ, Cmax, and Cτ.	Period 2, Day 10

Secondary

Measure	Time frame
Maraviroc plasma pharmacokinetic parameter: Tmax on Period 1, Day 5 and Period 2, Day 20.	Period 1, Day 5
Amprenavir and ritonavir plasma pharmacokinetic parameter: Tmax, on Period 2, Day 10 and Period 2, Day 20.	Period 2, Day 10
Safety and toleration assessed by spontaneous reporting of adverse events, vital signs, 12-lead ECG and laboratory safety assessments.	25 Days

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026